Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on August 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Results furnished in Exhibit 99.1, including management commentary and other disclosed matters
- Item 2.02 signals earnings information for investors, with detailed figures available in the attached press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $29.1M, down 2%; ETUARY sales rose to $28.0M while Etorel and Contiva declined under centralized procurement
- Full-year 2026 revenue guidance maintained at $100.5M-$111.0M despite Astellas collaboration revenue ending in March
- GAAP net loss $14.3M and EPS $(0.12), driven by R&D escalation, including $4.8M F351 milestone payment
- F351 NDA accepted by China’s CDE in May, advancing Gyre’s second major product candidate toward potential liver-fibrosis approval
- Cullgen acquisition closed for approximately $300M in stock, adding degrader and DAC pipelines but contributing to broader development complexity and spending
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.